Date: 2011-02-09
Type of information: Development agreement
Compound: PAP-1
Company: Circassia (UK) Airmid (USA)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: development
commercialisation
Action mechanism: PAP-1 is a potent and selective Kv1.3 inhibitors known, and has ideal topical delivery characteristics. The molecule is a highly specific immunosuppressant, acting on effector memory T-cells while leaving naïve and central memory T-cells intact, and has demonstrated impressive activity in psoriasis and atopic dermatitis models when applied topically.
Disease: psoriasis - atopic dermatitis
Details: Circassia, a specialty biopharmaceutical company focused on allergy, has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1.
Financial terms: Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.
Latest news:
